{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:54:33Z","timestamp":1781873673366,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.iotech.2026.101587","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:07:51Z","timestamp":1772863671000},"page":"101587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-3513","authenticated-orcid":false,"given":"M.","family":"Velasco Santiago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0968-6395","authenticated-orcid":false,"given":"R.S.","family":"Jurlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Albieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-2099","authenticated-orcid":false,"given":"I.M.","family":"Noringriis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9230-7644","authenticated-orcid":false,"given":"J.E.","family":"Sohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-936X","authenticated-orcid":false,"given":"A.H.","family":"Kverneland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"I.M.","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.iotech.2026.101587_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.iotech.2026.101587_bib2","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10304","key":"10.1016\/j.iotech.2026.101587_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.iotech.2026.101587_bib4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.iotech.2026.101587_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101587_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2026.101587_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.iotech.2026.101587_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy","volume":"12","author":"Bruera","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2494433","article-title":"Impact of steroid dose and timing on efficacy of combination PD-1\/CTLA-4 blockade","volume":"14","author":"Curkovic","year":"2025","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.iotech.2026.101587_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib14","first-page":"18.8.1","article-title":"Immune cell phenotyping using flow cytometry","volume":"66","author":"Pockley","year":"2015","journal-title":"Curr Protoc Toxicol"},{"key":"10.1016\/j.iotech.2026.101587_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1096096","article-title":"Advanced immunophenotyping: a powerful tool for immune profiling, drug screening, and a personalized treatment approach","volume":"14","author":"Preglej","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101587_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cll.2024.04.008","article-title":"Flow cytometric assessment of malignant hematologic disorders","volume":"44","author":"Hartzell","year":"2024","journal-title":"Clin Lab Med"},{"issue":"2","key":"10.1016\/j.iotech.2026.101587_bib18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"3","key":"10.1016\/j.iotech.2026.101587_bib19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cyto.a.24350","article-title":"Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre","volume":"101","author":"Ashhurst","year":"2022","journal-title":"Cytometry A"},{"issue":"7","key":"10.1016\/j.iotech.2026.101587_bib20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nbt.4314","article-title":"Dimensionality reduction for visualizing single-cell data using UMAP","volume":"37","author":"Becht","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.iotech.2026.101587_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729143","article-title":"The role of B cells in adult and paediatric liver injury","volume":"12","author":"Patel","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.iotech.2026.101587_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/cei\/uxab035","article-title":"Kidney infiltrating NK cells and NK-like T-cells in lupus nephritis: presence, localization, and the effect of immunosuppressive treatment","volume":"207","author":"Scheffschick","year":"2022","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/imr.13238","article-title":"Role of B cells in immune-related adverse events following checkpoint blockade","volume":"318","author":"Dhodapkar","year":"2023","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s43856-025-01164-3","article-title":"Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events","volume":"5","author":"van Eijs","year":"2025","journal-title":"Commun Med"},{"issue":"12","key":"10.1016\/j.iotech.2026.101587_bib26","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1007\/s00262-023-03541-0","article-title":"Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition","volume":"72","author":"van Eijs","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.iotech.2026.101587_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1292122","article-title":"Achilles\u2019 Heel of currently approved immune checkpoint inhibitors: immune related adverse events","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101587_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114172","article-title":"Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma","volume":"207","author":"Verheijden","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.iotech.2026.101587_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.iotech.2026.101587_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/87551225221116266","article-title":"Complications of corticosteroid therapy: a comprehensive literature review","volume":"38","author":"Koshi","year":"2022","journal-title":"J Pharm Technol"},{"issue":"10","key":"10.1016\/j.iotech.2026.101587_bib31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/CS20210042","article-title":"Mechanisms underlying immune-related adverse events during checkpoint immunotherapy","volume":"136","author":"Zhou","year":"2022","journal-title":"Clin Sci"},{"issue":"1","key":"10.1016\/j.iotech.2026.101587_bib32","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192179","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective","volume":"218","author":"Burke","year":"2021","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.iotech.2026.101587_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:02:25Z","timestamp":1781870545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S2590018826000067"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101587","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101587"}}